PL3601358T3 - Przeciwciała anty-trem2 i sposoby ich wykorzystania - Google Patents

Przeciwciała anty-trem2 i sposoby ich wykorzystania

Info

Publication number: PL3601358T3
Authority: PL; Poland
Prior art keywords: methods; trem2 antibodies; trem2; antibodies
Prior art date: 2017-08-03

Application number

PL18759461.9T

Other languages

English (en)

Inventor

Tina SCHWABE

Eric Brown

Philip KONG

Ilaria TASSI

Seung-Joo Lee

Arnon Rosenthal

Robert PEJCHAL

Nels P. NIELSON

Original Assignee

Alector Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-08-03

Filing date

2018-08-02

Publication date

2023-10-02

2018-08-02 Application filed by Alector Llc filed Critical Alector Llc

2023-10-02 Publication of PL3601358T3 publication Critical patent/PL3601358T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL18759461.9T 2017-08-03 2018-08-02 Przeciwciała anty-trem2 i sposoby ich wykorzystania PL3601358T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762541019P	2017-08-03	2017-08-03
US201862636095P	2018-02-27	2018-02-27
PCT/US2018/045068 WO2019028292A1 (en)	2017-08-03	2018-08-02	ANTI-TREM2 ANTIBODIES AND METHODS OF USE

Publications (1)

Publication Number	Publication Date
PL3601358T3 true PL3601358T3 (pl)	2023-10-02

Family

ID=63364160

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18759461.9T PL3601358T3 (pl)	2017-08-03	2018-08-02	Przeciwciała anty-trem2 i sposoby ich wykorzystania

Country Status (34)

Country	Link
US (3)	US10676525B2 (pl)
EP (2)	EP3601358B1 (pl)
JP (3)	JP2020533948A (pl)
KR (2)	KR102769231B1 (pl)
CN (3)	CN119192376A (pl)
AU (1)	AU2018311055B2 (pl)
BR (1)	BR112019022752A2 (pl)
CA (1)	CA3061755A1 (pl)
CL (2)	CL2019003093A1 (pl)
CO (1)	CO2019012210A2 (pl)
CR (3)	CR20230170A (pl)
DK (1)	DK3601358T5 (pl)
EC (1)	ECSP19078429A (pl)
ES (1)	ES2952982T3 (pl)
FI (1)	FI3601358T3 (pl)
HR (1)	HRP20230675T1 (pl)
HU (1)	HUE062436T2 (pl)
IL (2)	IL315241A (pl)
LT (1)	LT3601358T (pl)
MD (1)	MD3601358T2 (pl)
MX (2)	MX2019012868A (pl)
MY (1)	MY201526A (pl)
NZ (1)	NZ758301A (pl)
PE (1)	PE20200148A1 (pl)
PH (1)	PH12019502459A1 (pl)
PL (1)	PL3601358T3 (pl)
PT (1)	PT3601358T (pl)
RS (1)	RS64419B1 (pl)
SI (1)	SI3601358T1 (pl)
SM (1)	SMT202300281T1 (pl)
TW (3)	TWI868807B (pl)
UA (1)	UA129513C2 (pl)
WO (1)	WO2019028292A1 (pl)
ZA (2)	ZA201906730B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201700901SA (en)	2014-08-08	2017-03-30	Alector Llc	Anti-trem2 antibodies and methods of use thereof
CN106999585A (zh)	2014-09-28	2017-08-01	加利福尼亚大学董事会	对刺激性和非刺激性骨髓细胞的调节
JOP20190248A1 (ar)	2017-04-21	2019-10-20	Amgen Inc	بروتينات ربط مولد ضد trem2 واستخداماته
HRP20230675T1 (hr)	2017-08-03	2023-09-29	Alector Llc	Anti-trem2 protutijela i postupci njihove uporabe
CN111712258B (zh)	2017-12-12	2024-03-15	开拓免疫医疗公司	抗trem2抗体和相关方法
US20230132366A9 (en)	2018-11-26	2023-04-27	Denali Therapeutics Inc.	Methods for treating dysregulated lipid metabolism
AU2020226754A1 (en) *	2019-02-20	2021-09-16	Denali Therapeutics Inc.	Anti-TREM2 antibodies and methods of use thereof
PH12022551228A1 (en) *	2019-11-22	2023-06-14	Lilly Co Eli	Trem2 antibodies and uses thereof
US20230024528A1 (en) *	2019-12-05	2023-01-26	Alector Llc	Methods of use of anti-trem2 antibodies
CN115279790A (zh)	2020-01-13	2022-11-01	戴纳立制药公司	抗trem2抗体和其使用方法
TWI890727B (zh)	2020-01-13	2025-07-21	美商戴納立製藥公司	抗trem2 抗體及其使用方法
EP4110814A1 (en) *	2020-02-24	2023-01-04	Alector LLC	Methods of use of anti-trem2 antibodies
IL296992A (en) *	2020-04-03	2022-12-01	Alector Llc	Methods of use of anti-trem2 antibodies
CN117396510A (zh)	2021-05-14	2024-01-12	基因泰克公司	Trem2的激动剂
CA3242959A1 (en)	2021-12-17	2025-02-26	Denali Therapeutics Inc	POLYPEPTIDE ENGINEERING, LIBRARIES AND ENGINEERED POLYPEPTIDES FOR CD98 HEAVY CHAIN LINK AND TRANSFERRINE RECEIVER
AU2023225020A1 (en)	2022-02-23	2024-09-12	Alector Llc	Methods of use of anti-trem2 antibodies
US20250215077A1 (en)	2022-03-28	2025-07-03	Denali Therapeutics Inc.	Monovalent anti-trem2 binding molecules and methods of use thereof
EP4499695A1 (en)	2022-03-28	2025-02-05	Denali Therapeutics Inc.	Methods for treating brain glucose hypometabolism
EP4572772A1 (en)	2022-08-17	2025-06-25	Capstan Therapeutics, Inc.	Conditioning for in vivo immune cell engineering
JP2025529287A (ja)	2022-09-06	2025-09-04	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト
US12311033B2 (en)	2023-05-31	2025-05-27	Capstan Therapeutics, Inc.	Lipid nanoparticle formulations and compositions
WO2024253420A1 (ko) *	2023-06-09	2024-12-12	재단법인대구경북과학기술원	인간 trem2 단백질에 특이적으로 결합하는 인간 항체 및 이의 용도
WO2025046298A2 (en)	2023-09-01	2025-03-06	iTeos Belgium SA	Anti-trem2 antibodies and methods of use
US20250127728A1 (en)	2023-10-05	2025-04-24	Capstan Therapeutics, Inc.	Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025166058A1 (en) *	2024-01-31	2025-08-07	Alector Llc	Multi-specific proteins that bind to trem2 and transferrin receptor and uses therefor
US20250302763A1 (en)	2024-02-22	2025-10-02	Capstan Therapeutics, Inc.	Immune engineering amplification
CN118546252A (zh) *	2024-04-02	2024-08-27	上海宏成药业有限公司	抗trem2抗体及其用途
WO2025217454A2 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4657760A (en)	1979-03-20	1987-04-14	Ortho Pharmaceutical Corporation	Methods and compositions using monoclonal antibody to human T cells
DK187280A (da)	1980-04-30	1981-10-31	Novo Industri As	Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5206344A (en)	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en)	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
DE69133566T2 (de)	1990-01-12	2007-12-06	Amgen Fremont Inc.	Bildung von xenogenen Antikörpern
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5229275A (en)	1990-04-26	1993-07-20	Akzo N.V.	In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko)	1990-08-29	2000-11-15	젠팜인터내셔날,인코포레이티드	이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
WO1993006217A1 (en)	1991-09-19	1993-04-01	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
FI941572L (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
AU3178993A (en)	1991-11-25	1993-06-28	Enzon, Inc.	Multivalent antigen-binding proteins
ATE419355T1 (de)	1992-02-06	2009-01-15	Novartis Vaccines & Diagnostic	Marker für krebs und biosynthetisches bindeprotein dafür
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
ATE149570T1 (de)	1992-08-17	1997-03-15	Genentech Inc	Bispezifische immunoadhesine
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
JP4312259B2 (ja)	1995-04-27	2009-08-12	アムジェンフレモントインク．	免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU7378096A (en)	1995-09-28	1997-04-17	Alexion Pharmaceuticals, Inc.	Porcine cell interaction proteins
DE19544393A1 (de)	1995-11-15	1997-05-22	Hoechst Schering Agrevo Gmbh	Synergistische herbizide Mischungen
DE69738539T2 (de)	1996-12-03	2009-03-26	Amgen Fremont Inc.	Vollkommen humane Antikörper die EGFR binden
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
JP4460155B2 (ja)	1997-12-05	2010-05-12	ザ・スクリプス・リサーチ・インステイチユート	マウス抗体のヒト化
GB9809951D0 (en)	1998-05-08	1998-07-08	Univ Cambridge Tech	Binding molecules
EP1090118A2 (en)	1998-06-26	2001-04-11	Incyte Pharmaceuticals, Inc.	Human signal peptide-containing proteins
JP2003512821A (ja)	1999-10-04	2003-04-08	メディカゴインコーポレイテッド	外来性遺伝子の転写調節方法
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
US6849425B1 (en) *	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
DK1272647T3 (en)	2000-04-11	2014-12-15	Genentech Inc	Multivalent antibodies and uses thereof
US8981061B2 (en)	2001-03-20	2015-03-17	Novo Nordisk A/S	Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en)	2001-03-20	2009-03-26	Bioxell S.P.A.	Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en)	2001-03-20	2013-11-12	Marco Colonna	A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en)	2001-03-20	2012-07-31	Cosmo Research & Development S.P.A.	Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
AU2002334997A1 (en)	2001-10-12	2003-04-22	Schering Corporation	Use of bispecific antibodies to regulate immune responses
JP2004073182A (ja)	2002-05-24	2004-03-11	Takeda Chem Ind Ltd	インスリン抵抗性改善剤
US7556926B2 (en)	2002-05-24	2009-07-07	Takeda Pharmaceuticals Company Ltd.	Methods for screening insulin-sensitizing agents
WO2004041170A2 (en)	2002-11-01	2004-05-21	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
JP2006504971A (ja)	2002-11-01	2006-02-09	ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト	マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
WO2004058178A2 (en)	2002-12-23	2004-07-15	Schering Corporation	Uses of mammalian cytokine; related reagents
WO2004074506A2 (en)	2003-02-13	2004-09-02	Mergen Ltd	Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
KR20070107687A (ko)	2004-12-31	2007-11-07	제넨테크, 인크.	Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
US7700099B2 (en)	2005-02-14	2010-04-20	Merck & Co., Inc.	Non-immunostimulatory antibody and compositions containing the same
US8101345B1 (en)	2005-03-25	2012-01-24	Isis Pharmaceuticals, Inc.	Proinflammatory nucleic acids
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
DK2359834T5 (en)	2006-03-15	2017-02-06	Alexion Pharma Inc	Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
DE202006007499U1 (de)	2006-05-11	2007-01-11	Osaka University	Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
CN105837690A (zh)	2006-06-12	2016-08-10	新兴产品开发西雅图有限公司	具有效应功能的单链多价结合蛋白
WO2008042261A2 (en) *	2006-09-28	2008-04-10	Elusys Therapeutics, Inc.	Anti-anthrax antibody, formulations thereof, and methods of use
US7673853B2 (en)	2006-10-12	2010-03-09	Cordell Eldred Ebeling	Fencing section with adjustable fencing members
UY30776A1 (es)	2006-12-21	2008-07-03	Medarex Inc	Anticuerpos cd44
WO2008088849A2 (en) *	2007-01-16	2008-07-24	Wyeth	Inflammation treatment, detection and monitoring via trem-1
CA2697193C (en)	2007-09-14	2017-06-06	Adimab, Inc.	Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en)	2007-09-14	2014-11-04	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
WO2009046313A2 (en)	2007-10-05	2009-04-09	University Of Maryland, Baltimore	Novel compositions and methods for stimulating erythropoiesis in a mammal
KR100960684B1 (ko)	2008-02-22	2010-05-31	전남대학교산학협력단	Ｇａ733-2 발현 억제제로서의 ｔｒｅｍ-2 유전자, 및 이를포함하는 형질전환 동물 및 이의 사용방법
EP2186928A1 (en)	2008-11-14	2010-05-19	Enthone, Inc.	Method for the post-treatment of metal layers
FR2945538B1 (fr)	2009-05-12	2014-12-26	Sanofi Aventis	Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
WO2011047097A2 (en)	2009-10-13	2011-04-21	Sigalov Alexander B	Inhibition of trem receptor signaling with peptide variants
JP6184695B2 (ja)	2009-12-04	2017-08-23	ジェネンテック，インコーポレイテッド	多重特異性抗体、抗体アナログ、組成物、及び方法
TWI653333B (zh) *	2010-04-01	2019-03-11	安進研究（慕尼黑）有限責任公司	跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
WO2012009568A2 (en)	2010-07-16	2012-01-19	Adimab, Llc	Antibody libraries
UA112062C2 (uk)	2010-10-04	2016-07-25	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cd33-зв'язувальний агент
WO2012088302A2 (en)	2010-12-22	2012-06-28	Abbott Laboratories	Half immunoglobulin binding proteins and uses thereof
WO2012088290A2 (en)	2010-12-22	2012-06-28	Abbott Laboratories	Tri-variable domain binding proteins and uses thereof
TWI559929B (en) *	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130309223A1 (en)	2012-05-18	2013-11-21	Seattle Genetics, Inc.	CD33 Antibodies And Use Of Same To Treat Cancer
WO2014074942A1 (en)	2012-11-08	2014-05-15	Illumina, Inc.	Risk variants of alzheimer's disease
CA2825821A1 (en)	2013-08-28	2015-02-28	Chiesi Farmaceutici S.P.A.	1-phenylalkanecarboxylic acid derivatives for the treatment of alzheimer's disease and multiple sclerosis
WO2015037000A1 (en)	2013-09-11	2015-03-19	Compugen Ltd	Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
US20170218091A1 (en)	2014-07-03	2017-08-03	Abbvie Inc.	Monovalent binding proteins
SG11201700901SA (en)	2014-08-08	2017-03-30	Alector Llc	Anti-trem2 antibodies and methods of use thereof
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
CN106999585A (zh) *	2014-09-28	2017-08-01	加利福尼亚大学董事会	对刺激性和非刺激性骨髓细胞的调节
WO2016064895A1 (en) *	2014-10-20	2016-04-28	The Brigham And Women's Hospital, Inc.	Targeting apolipoprotein e (apoe) in neurologic disease
AU2016246695A1 (en)	2015-04-07	2017-10-26	Genentech, Inc.	Antigen binding complex having agonistic activity and methods of use
WO2016187339A1 (en)	2015-05-18	2016-11-24	Synaptec Development Llc	GALANTAMINE CLEARANCE OF AMYLOIDß
US20180194861A1 (en)	2015-07-10	2018-07-12	Abbvie Inc.	IgM- or IgE-Modified Binding Proteins and Uses Thereof
WO2017058866A1 (en)	2015-09-28	2017-04-06	Precision Immune, Inc.	Anti-trem2 antibodies and uses thereof
JP7725185B2 (ja) *	2015-10-06	2025-08-19	アレクトルエルエルシー	抗ｔｒｅｍ２抗体及びその使用方法
KR102415925B1 (ko) *	2016-01-11	2022-07-04	삼성디스플레이 주식회사	표시장치
US11066456B2 (en)	2016-02-25	2021-07-20	Washington University	Compositions comprising TREM2 and methods of use thereof
JP2019531332A (ja)	2016-07-22	2019-10-31	ドイチェスツェントルムフュールノイロデゲネラティフェアークランクンゲンエー．ファウ．（デーツェットエンエー）	Ｔｒｅｍ２切断モジュレーター及びその使用
SG11201900744SA (en)	2016-08-12	2019-02-27	Janssen Biotech Inc	Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
WO2018134815A2 (en)	2017-01-17	2018-07-26	Yeda Research And Development Co. Ltd.	Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
WO2018140831A2 (en)	2017-01-27	2018-08-02	Silverback Therapeutics, Inc.	Tumor targeting conjugates and methods of use thereof
US10457717B2 (en)	2017-02-17	2019-10-29	Denali Therapeutics Inc.	Engineered polypeptides
JOP20190248A1 (ar) *	2017-04-21	2019-10-20	Amgen Inc	بروتينات ربط مولد ضد trem2 واستخداماته
US20190008812A1 (en)	2017-07-07	2019-01-10	Washington University	Methods for treating microglial dysfunction
BR112020001060A2 (pt)	2017-07-27	2020-07-14	Novartis Ag	variantes de trem2 resistentes a shedase
HRP20230675T1 (hr)	2017-08-03	2023-09-29	Alector Llc	Anti-trem2 protutijela i postupci njihove uporabe
PE20200486A1 (es)	2017-08-03	2020-03-03	Alector Llc	Anticuerpos anti-cd33 y metodos para utilizarlos
CA3075285A1 (en)	2017-09-14	2019-03-21	Denali Therapeutics Inc.	Anti-trem2 antibodies and methods of use thereof
BR112020006661A2 (pt)	2017-10-03	2020-10-13	Prevail Therapeutics, Inc.	terapias de genes para distúrbios lipossomais
WO2019079529A1 (en)	2017-10-17	2019-04-25	The Translational Genomics Research Institute	TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS
CN111712258B (zh)	2017-12-12	2024-03-15	开拓免疫医疗公司	抗trem2抗体和相关方法
US12091455B2 (en)	2018-02-14	2024-09-17	Yale University	Compositions for modulation of a TREM or TREML protein and methods of use
IL296992A (en) *	2020-04-03	2022-12-01	Alector Llc	Methods of use of anti-trem2 antibodies
CN117396510A (zh) *	2021-05-14	2024-01-12	基因泰克公司	Trem2的激动剂

2018
- 2018-08-02 HR HRP20230675TT patent/HRP20230675T1/hr unknown
- 2018-08-02 WO PCT/US2018/045068 patent/WO2019028292A1/en not_active Ceased
- 2018-08-02 DK DK18759461.9T patent/DK3601358T5/da active
- 2018-08-02 BR BR112019022752-0A patent/BR112019022752A2/pt not_active Application Discontinuation
- 2018-08-02 MD MDE20200147T patent/MD3601358T2/ro unknown
- 2018-08-02 HU HUE18759461A patent/HUE062436T2/hu unknown
- 2018-08-02 MY MYPI2019006404A patent/MY201526A/en unknown
- 2018-08-02 CR CR20230170A patent/CR20230170A/es unknown
- 2018-08-02 PT PT187594619T patent/PT3601358T/pt unknown
- 2018-08-02 CR CR20230169A patent/CR20230169A/es unknown
- 2018-08-02 KR KR1020197031793A patent/KR102769231B1/ko active Active
- 2018-08-02 JP JP2019559017A patent/JP2020533948A/ja active Pending
- 2018-08-02 IL IL315241A patent/IL315241A/en unknown
- 2018-08-02 SI SI201830958T patent/SI3601358T1/sl unknown
- 2018-08-02 TW TW112126799A patent/TWI868807B/zh active
- 2018-08-02 PE PE2019002183A patent/PE20200148A1/es unknown
- 2018-08-02 NZ NZ758301A patent/NZ758301A/en unknown
- 2018-08-02 UA UAA201910722A patent/UA129513C2/uk unknown
- 2018-08-02 CR CR20190485A patent/CR20190485A/es unknown
- 2018-08-02 TW TW113146124A patent/TW202511296A/zh unknown
- 2018-08-02 CN CN202411407317.7A patent/CN119192376A/zh active Pending
- 2018-08-02 LT LTEPPCT/US2018/045068T patent/LT3601358T/lt unknown
- 2018-08-02 CN CN202411415268.1A patent/CN119192377A/zh active Pending
- 2018-08-02 TW TW107126810A patent/TWI811229B/zh active
- 2018-08-02 EP EP18759461.9A patent/EP3601358B1/en active Active
- 2018-08-02 MX MX2019012868A patent/MX2019012868A/es unknown
- 2018-08-02 IL IL270235A patent/IL270235B2/en unknown
- 2018-08-02 RS RS20230644A patent/RS64419B1/sr unknown
- 2018-08-02 FI FIEP18759461.9T patent/FI3601358T3/fi active
- 2018-08-02 AU AU2018311055A patent/AU2018311055B2/en active Active
- 2018-08-02 CN CN201880027792.8A patent/CN110621696B/zh active Active
- 2018-08-02 SM SM20230281T patent/SMT202300281T1/it unknown
- 2018-08-02 ES ES18759461T patent/ES2952982T3/es active Active
- 2018-08-02 EP EP23166216.4A patent/EP4248996A3/en active Pending
- 2018-08-02 CA CA3061755A patent/CA3061755A1/en active Pending
- 2018-08-02 PL PL18759461.9T patent/PL3601358T3/pl unknown
- 2018-08-02 KR KR1020257004632A patent/KR20250026882A/ko active Pending
- 2018-08-03 US US16/054,680 patent/US10676525B2/en active Active
2019
- 2019-10-11 ZA ZA2019/06730A patent/ZA201906730B/en unknown
- 2019-10-28 CL CL2019003093A patent/CL2019003093A1/es unknown
- 2019-10-28 MX MX2024001803A patent/MX2024001803A/es unknown
- 2019-10-30 CO CONC2019/0012210A patent/CO2019012210A2/es unknown
- 2019-10-30 PH PH12019502459A patent/PH12019502459A1/en unknown
- 2019-10-31 EC ECSENADI201978429A patent/ECSP19078429A/es unknown
2020
- 2020-03-30 US US16/835,140 patent/US11634489B2/en active Active
- 2020-07-28 CL CL2020001974A patent/CL2020001974A1/es unknown
2022
- 2022-10-10 ZA ZA2022/11057A patent/ZA202211057B/en unknown
- 2022-11-22 JP JP2022186859A patent/JP7554247B2/ja active Active
2023
- 2023-02-24 US US18/174,499 patent/US20230312712A1/en active Pending
2024
- 2024-06-05 JP JP2024091312A patent/JP2024147536A/ja active Pending

Also Published As

Publication number	Publication date
CN110621696A (zh)	2019-12-27
IL270235B1 (en)	2024-10-01
MD3601358T2 (ro)	2023-10-31
NZ758301A (en)	2023-07-28
UA129513C2 (uk)	2025-05-21
CA3061755A1 (en)	2019-02-07
CR20190485A (es)	2020-02-10
US20190040130A1 (en)	2019-02-07
CR20230169A (es)	2023-05-31
CN119192376A (zh)	2024-12-27
AU2018311055A1 (en)	2019-11-14
CN110621696B (zh)	2024-10-25
MX2019012868A (es)	2019-11-28
IL315241A (en)	2024-10-01
MX2024001803A (es)	2024-03-06
PE20200148A1 (es)	2020-01-17
JP2023029882A (ja)	2023-03-07
US20200317776A1 (en)	2020-10-08
TW202511296A (zh)	2025-03-16
US20230312712A1 (en)	2023-10-05
US11634489B2 (en)	2023-04-25
ES2952982T3 (es)	2023-11-07
KR20250026882A (ko)	2025-02-25
WO2019028292A1 (en)	2019-02-07
LT3601358T (lt)	2023-08-10
IL270235B2 (en)	2025-02-01
EP3601358A1 (en)	2020-02-05
FI3601358T3 (fi)	2023-07-20
IL270235A (pl)	2019-12-31
JP2024147536A (ja)	2024-10-16
CL2020001974A1 (es)	2020-10-23
CR20230170A (es)	2023-05-31
EP3601358B1 (en)	2023-05-17
HUE062436T2 (hu)	2023-11-28
TWI868807B (zh)	2025-01-01
DK3601358T3 (da)	2023-07-31
DK3601358T5 (da)	2024-09-02
AU2018311055B2 (en)	2025-05-29
ECSP19078429A (es)	2020-02-28
TWI811229B (zh)	2023-08-11
SMT202300281T1 (it)	2023-11-13
TW202342547A (zh)	2023-11-01
HRP20230675T1 (hr)	2023-09-29
EP4248996A2 (en)	2023-09-27
EP4248996A3 (en)	2023-11-08
SI3601358T1 (sl)	2023-10-30
JP2020533948A (ja)	2020-11-26
KR102769231B1 (ko)	2025-02-20
KR20200033794A (ko)	2020-03-30
PT3601358T (pt)	2023-08-30
RS64419B1 (sr)	2023-09-29
ZA202211057B (en)	2024-02-28
CN119192377A (zh)	2024-12-27
CL2019003093A1 (es)	2020-03-20
JP7554247B2 (ja)	2024-09-19
MY201526A (en)	2024-02-27
CO2019012210A2 (es)	2020-04-01
US10676525B2 (en)	2020-06-09
PH12019502459A1 (en)	2020-07-20
TW201912654A (zh)	2019-04-01
BR112019022752A2 (pt)	2020-05-19
ZA201906730B (en)	2023-04-26

Publication	Publication Date	Title
PL3601358T3 (pl)	2023-10-02	Przeciwciała anty-trem2 i sposoby ich wykorzystania
IL271025A (en)	2020-01-30	Multibiotic agents and methods of using the same
LT3618863T (lt)	2023-10-10	Anti-tigit antikūnai ir jų panaudojimo būdai
PL3250610T3 (pl)	2024-01-29	Przeciwciała anty-FcRn i sposoby ich stosowania
IL272069A (en)	2020-03-31	Dosage regimens of anti-lag-3 antibodies and uses thereof
PL3353210T3 (pl)	2025-02-24	Przeciwciała anty-TIGIT i sposoby stosowania
PL3551660T3 (pl)	2024-02-26	Przeciwciała anty-ctla-4 i sposoby ich stosowania
DK3653221T3 (da)	2022-10-24	Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
IL259713A (en)	2018-07-31	Anti-dr5 antibodies and methods of use thereof
KR20180084817A (ko)	2018-07-25	항-siglec-9 항체 및 이의 이용 방법
PL3383916T3 (pl)	2023-06-12	Przeciwciała anty-cd73 i ich zastosowania
IL251970B (en)	2021-12-01	Anti-cd79b antibodies and methods of use
IL263657A (en)	2019-01-31	Anti-c5 antibodies and methods of use
IL254068A0 (en)	2017-10-31	Anti-dll3 chimeric antigen receptors and methods of use
IL254670A0 (en)	2017-11-30	Humanized anti-c1s antibodies and methods of use thereof
PL3280441T3 (pl)	2022-02-21	Przeciwciała przeciwko sortilinie i sposoby ich stosowania
HUE058755T2 (hu)	2022-09-28	Anti-tigit antigénkötõ proteinek és felhasználásuk módszerei
PL3618928T3 (pl)	2023-05-02	Przeciwciała antysortylinowe i sposoby ich stosowania
SI3303394T1 (sl)	2020-10-30	Protitelesa proti-CTLA-4 in postopki njihove uporabe
PL3148579T3 (pl)	2021-07-19	Przeciwciała anty-gitr i sposoby ich zastosowania
DK3310812T3 (da)	2025-09-29	Anti-HER2-antistoffer og fremgangsmåder til anvendelse
DK3525583T3 (da)	2025-10-27	Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
IL285401A (en)	2021-09-30	Anti-clec2d antibodies and methods of use thereof
CR20180296A (es)	2018-08-10	ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO
EP3630046C0 (en)	2024-12-25	ANTI-DOUBLECORTIN-LIKE KINASE 1 ANTIBODIES AND METHODS OF USE THEREOF